Susquehanna International Group
NPCE icon

Susquehanna International Group’s Neuropace NPCE Stock Holding History

Susquehanna International Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,300
Closed -$182K – 13419
2025
Q2 		$182K Buy
+16,300
New +$204K ﹤0.01% 11307

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Susquehanna International Group's NPCE Position: Q1 2026 in Review

Susquehanna International Group increased its Neuropace (NPCE) stake by 149% in Q1 2026, buying an estimated $226K and bringing the position to 25,180 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #10656.

Susquehanna International Group first reported a position in NPCE in Q1 2023 and has held it in 8 quarters since. The position peaked at $2.69M in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Susquehanna International Group held 25,180 shares of Neuropace worth $331K as of Q1 2026.
  • Susquehanna International Group bought 15,059 Neuropace shares in Q1 2026, an estimated $226K.
  • Neuropace made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10656 holding.
  • Susquehanna International Group first reported a position in Neuropace in Q1 2023 and has held it in 8 quarters since.
  • Susquehanna International Group's Neuropace position peaked at $2.69M in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.